Background {#S0001}
==========

Reliable clinical tools for assessing patient's physiological reserves are of great importance in helping physicians make decisions about future treatments and appraising patients' prognosis. The Eastern Cooperative Oncology Group (ECOG) performance status (ECOG-PS) score is a good example for such tools. In recent years, additional measures have been proposed in an attempt to evaluate patients' capacity to cope with, at times, highly aggressive treatments. The frailty status, along with sarcopenia evaluation, were suggested as being parallel to determination of PS and could potentially improve the selection of patients eligible for more aggressive therapies.[@CIT0001] Many authors relate to sarcopenia and frailty as a continuum, or as a cause and outcome. Cederholm T. even connect this, so-called, overlapping continuum to mortality, stating that "... robustness passes from sarcopenia over frailty to disability leading eventually to a mortal outcome".[@CIT0002] Lorenzi et al defined sarcopenia as the "biologic substrate" of frailty and tried to establish an association between leukocytes telomere length and this continuum.[@CIT0003] Wilson et al defined sarcopenia as the "precursor syndrome or the physical manifestation of frailty".[@CIT0004] There is no doubt that this continuum is associated with nutritional status but also with inherited patterns of muscle mass and distribution. The overall result may define the patients\' robustness and potential for successful combat of potentially lethal illnesses, such as lung cancer.

Subjective, qualitative measures for sarcopenia and frailty, such as the "eyeball test", tend to be less accurate.[@CIT0005] Therefore, we focused on two quantitative parameters of frailty that could add important information to the cancer patients' clinical, overall evaluation, imaging-based sarcopenia evaluation and alanine aminotransferase (ALT) serum levels.

Sarcopenia evaluation via muscle mass assessment in computed tomography scans {#S0002}
=============================================================================

Sarcopenia is defined as a change in body composition that includes a pathological decrease in muscle mass which affects performance.[@CIT0006] It is generally assigned to the realm of geriatric medicine, but at all phases of life, it is associated with a huge burden of both financial and functional costs.[@CIT0007] Several methods are available for evaluation of the overall skeletal muscle mass, with different accuracy levels. These include dual-energy X-ray absorptiometry and bioelectrical impedance analysis, the first being more accurate than the second but requires specialized equipment. Computed tomography (CT) is considered today the gold standard for sarcopenia evaluation due to its accuracy in body composition measurement and its availability in the clinical setting.[@CIT0008]--[@CIT0010]

Several studies have shown that sarcopenia can be quantified through an estimation of three-dimensional muscle mass at the level of L3 vertebra on two-dimensional planar sections (cm^2^ of muscle tissue) of CT scans. This cross-section was found to be the most accurate predictor to whole-body muscle mass[@CIT0011] The muscle area at L3 vertebra level, divided by the patient height (squared), is accepted as a surrogate marker of sarcopenia and cachexia, and is also known as the third lumbar vertebra skeletal muscle index (L3SMI).[@CIT0009],[@CIT0012],[@CIT0013] L3SMI were found to be clinically predictive and associated with clinical endpoints such as survival and length of hospitalization in various patients' populations including postliver transplantation[@CIT0010],[@CIT0012] and in various cancer types.[@CIT0013]--[@CIT0016]

ALT activity in the peripheral blood {#S0003}
====================================

ALT (SGPT) is a liver enzyme, commonly monitored in routine bloodwork. Its biochemical activity is catalyzing pyruvate to alanine reaction in the skeletal muscle and catalyzing alanine to pyruvate reaction in the liver[@CIT0017] It is commonly used as a biomarker for hepatocellular injury. No data have been available regarding the clinical significance of lower-than-normal ALT values. Recently, several publications have demonstrated a low serum ALT activity to be associated with shortened survival in middle-aged healthy adults,[@CIT0018] and in patients hospitalized for various causes[@CIT0019] Low ALT values, potentially representing low muscle mass (sarcopenia), may be associated with increased frailty and subsequently shortened survival.

Lung cancer is the most common cancer worldwide, and it the most common cause of cancer-related death[@CIT0020] The most common type of lung cancer is non-small cell lung cancer (NSCLC), amounting to about 80% of all lung cancers. Lung cancer patients are mostly elderly and with significant comorbidities; thus, fragility assessment in those patients is a crucial element of their initial and ongoing evaluation. Both ALT and L3SMI values have the advantage of being quantitative parameters in the assessment of frailty, and are available to clinicians in the routine clinical practice (ALT being part of routine bloodworks and L3SMI easily derived from CT scans done with every new case of lung cancer diagnosis). We conducted the current research in order to examine whether ALT and L3SMI carry prognostic value in patients with NSCLC.

Methods {#S0004}
=======

Study population {#S0004-S2001}
----------------

We retrospectively studied records of lung cancer patients diagnosed, treated and followed in a tertiary referral oncology center, the Chaim Sheba Institute of Oncology, from September 2011 to November 2014. For this study, adult (over 18 years of age) patients with a diagnosis of NSCLC were included. Additional laboratory and clinical data were collected from patients' records. Included were only patients that performed a CT scan that included L3 vertebra, performed at any time within 2 months of diagnosis. As mentioned earlier, the L3 level was included, as part of the standard chest CT, in all our patients' population and CT scans were done for both diagnosis and follow-up assessments. Cases with elevated ALT levels (above the upper limit of normal value in the local laboratory; 40 IU/L), representing hepatocellular liver damage, were excluded, as were cases with missing relevant data (weight or height measurements, laboratory results).

Variables measurement and definition {#S0004-S2002}
------------------------------------

Sarcopenia was evaluated using L3SMI, based on CT scans of the study population, performed within 2 months of pathologic diagnosis. This 2-month period was arbitrarily determined in order to have a sarcopenia assessment that would be as close as possible to the premorbid condition of patients (prior to disease progression and treatment results). Skeletal muscle area was calculated using AW Server (General Electric Healthcare Inc., USA) and performed by one investigator (PD) after a thorough instruction by a radiology expert (DLC), including cross-verification of results (18 review cases, correlation coefficient: R =0.996, *p*\<0.001). The muscle area was corrected for the slice thickness and divided by the patient squared height. L3SMI is reported with cm^2^/m^2^ units. The study population was divided into two groups of normal and low L3SMI, according to threshold values described previously[@CIT0021] low L3SMI was defined as under 41 cm^2^/m^2^ for females and under 53 cm^2^/m^2^ for males. Demographic information (including age, sex and marital status), cancer type, disease stage at diagnosis and ECOG-PS were obtained from the Oncology Institute Working Registry. Blood levels of ALT, albumin, hemoglobinand creatinine at the time of diagnosis were obtained manually from electronical medical records for the study population, as were past diagnosis of comorbidities including diabetes mellitus, chronic kidney disease, cerebrovascular disease, chronic obstructive pulmonary disease and ischemic heart disease.

Outcome and definition {#S0004-S2003}
----------------------

The primary outcome was all-cause mortality. Mortality data were obtained from the national Israeli Population registry in August 2017. Follow-up duration was calculated from diagnosis date to mortality or end of study.

Statistical analysis {#S0004-S2004}
--------------------

Categorical variables were described as number and percentage. Continuous variables were examined for their distribution using histogram and Q--Q plot and described as mean and standard deviation for normally distributed variables or median and IQR for other variables. Continuous variables were compared between categories using Kruskal Wallis and Mann--Whitney tests. Length of follow-up was described using reverse censoring method. Kaplan--Meier curve was used to describe mortality, and the log-rank test was applied to compare between L3SMI categories. All variables were explored for an association with all-cause mortality using univariate Cox regression. The set of covariates included in the multiple regression analysis were age, sex and variables that were associated with the studied outcome at a significant level of *p*\<0.2 in the univariate analysis. Propensity score matching was performed in order to control of baseline characteristics between the normal and low L3SMI groups. Multivariate logistic regression on all patients' baseline characteristics was used to calculate the propensity score as the probability of patients to be in a low L3SMI group. Patients were matched according to propensity score, and an upmost difference of 5% was considered acceptable. Matched groups were compared using McNemar test for categorical variables, and paired sample *t*-tests or Wilcoxon test for continued variables. Stratified Cox regression was used to evaluate the HR between the groups after the matching. All statistical tests were two-sided, and a *p*-value \<0.05 was considered significant. All statistical analyses were performed using SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY, USA).

Results {#S0005}
=======

Patient characteristics {#S0005-S2001}
-----------------------

Records of 203 patients diagnosed with lung cancer were obtained. Of those, 175 were diagnosed with NSCLC. Twenty-one patients were excluded due to missing height and/or weight data, 9 were excluded due to unavailable laboratory results, 2 for elevated ALT values and 3 for missing relevant CT slides (ie, missing L3 sections). The remaining 140 patients were included in our analysis (patients' characteristics described in [Table 1](#T0001){ref-type="table"}). The median follow-up was 1.9 years (range: 1 month to 6.4 years). Event-free follow-up duration range was 2.8 years--6.4 years.Table 1Patients' characteristics -- whole cohortPatient characteristics (n=140)**Demographics**Sex -- female, n (%)61 (43.6)Age (years), median (IQR)66 (62--73)Weight (kg), median (IQR)70 (60.1--78.9)**Marital status, n(%)**Married105 (75)Single5 (3.6)Widowed16 (11.4)Divorced14 (10)**Disease characteristics, n(%)**Stage at diagnosis, n (%)116 (11.45)216 (11.45)345 (32.1)463 (45)**ECOG performance status, n(%)**054 (38.6)149 (35)≥237 (26.4)Low L3SMI (\<41 cm^2^/m^2^ for females and \<53 cm^2^/m^2^ for males), n (%)92 (65.7)L3SMI (cm^2^/m^2^) whole cohort, median (IQR)39.88 (26.4--50.82)L3SMI (cm^2^/m^2^) -- males, median (IQR)47.35 (28.76--56.16)L3SMI (cm^2^/m2) -- females, median (IQR)37.05 (22.46--43.28)**Background diagnoses, n(%)**Ischemic heart disease35 (25)Chronic kidney disease7 (5)Diabetes mellitus27 (19.3)S/*P* cerebrovascular disease8 (5.7)COPD18 (12.9)**Laboratory parameters**ALT (IU/L), median (IQR)17 (12--24)Creatinine (IU/L), median (IQR)0.92 (0.82--1.08)Albumin (IU/L), mean±SD3.75±0.5Hemoglobin (IU/L), mean±SD12.5±1.7[^2]

The cohort consisted of 56% males, and the median age at diagnosis was 66 years (range 37--86). Over 77% of participants were diagnosed with NSCLC stages 3 and 4, while similar proportions were diagnosed with ECOG PS of 0 or 1. Low L3SMI was common amongst our patient population (65.7%). Low ALT values were also common in this patient population with a median value of 17 IU/L (normal range 7--45 IU/L), while the mean albumin values were only mildly lower than normal (3.75 gr/dL ±0.5). As shown in [Table 1](#T0001){ref-type="table"}, aside from lung cancer, there was no other significant load of morbidity in our patients' population, potentially contributing to excess mortality.

ECOG PS, weight, ALT and albumin levels were found to be distributed differently between the patients with normal L3SMI and patients with low L3SMI, as can be seen in [Table 2](#T0002){ref-type="table"}. Therefore, matching was performed, as described in the "Methods" section, and 34 pairs were identified.Table 2Patient characteristics by L3SMI groups**Patient characteristicsLow L3SMI (n=92)Normal L3SMI (n=48)*p*-valueDemographics**Sex -- female, n (%)40 (43.5)21 (43.8)0.975Age (years), median (IQR)66 (62--73.75)65 (31--70.5)0.424Weight (kg), median (IQR)67.5 (58--75)73.5 (64--85.75)**0.008Marital status, n(%)**Married66 (71.7)39 (81.3)0.106Single5 (5.4)0 (0)Widowed9 (9.8)7 (14.6)Divorced12 (13)2 (9.8)**Disease characteristics, n(%)**Stage at diagnosis, n (%)17 (7.6)9 (18.8)0.251211 (12)5 (10.4)332 (34.8)13 (27.1)442 (45.7)21 (43.8)**ECOG performance status, n(%)**032 (34.8)22 (45.8)**0.008**128 (30.4)21 (43.8)\>232 (34.8)5 (10.4)**Background diagnoses, n(%)**Ischemic heart disease23 (25)12 (25)1.00Chronic kidney disease2 (2.2)5 (10.4)0.034Diabetes mellitus16 (17.4)11 (22.9)0.432S/*P* cerebrovascular disease8 (8.7)0 (0)0.035COPD13 (14.1)5 (10.4)0.533Laboratory parametersALT (IU/L), median (IQR)16 (12--22)20 (13.25--28.75)**0.043**ALT below 17 IU/L (N, %)49 (53.3%)16 (33.3%)**0.025**Creatinine (IU/L), median (IQR)0.905 (0.81--1.08)0.945 (0.83--1.09)0.604Albumin (IU/L), mean±SD3.69±0.553.88±0.41**0.024**Hemoglobin (IU/L), mean±SD12.35±1.812.88±1.60.091[^3][^4]

Association between L3SMI and ECOG PS {#S0005-S2002}
-------------------------------------

Lower L3SMI values were found to be in correlation with poor ECOG PS in males, while no such correlation was found among female patients (*p*=0.032 for males ([Figure 1](#F0001){ref-type="fig"}), *p*=0.904 for females). Males with ECOG PS score of "0" had L3SMI (median 52.9, IQR 44.3--59.6) that did not differ significantly (*p*=0.138) from that in males with ECOG PS score of "1" (median 46.1, IQR 26--56.4). However, in male patients with ECOG PS score of 2 and above ("2+"), the L3SMI (median 41.3, IQR 27.6--48.7) was significantly lower than in male patients with ECOG PS score of "0" (*p*=0.005) but not from that in males with ECOG PS score of "1" (*p*=0.498).Figure 1L3SMI correlation with ECOG performance status in males.**Abbreviations:** CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; L3SMI, L3 skeletal muscle index.

Mortality {#S0005-S2003}
---------

During the follow-up period, 102 (72.9%) of the patients died. Patients with low L3SMI were at a significantly higher risk for mortality, compared to normal values ([Figure 2](#F0002){ref-type="fig"}).Figure 2Kaplan--Meier mortality curve according to L3SMI.**Abbreviation:** L3SMI, L3 skeletal muscle index.

Univariate analysis of parameters associated with increased risk of mortality {#S0005-S2004}
-----------------------------------------------------------------------------

Results of univariate analysis are presented in [Table 3](#T0003){ref-type="table"}. Low L3SMI was found to be associated with increased risk of mortality (77.2% of patients with low L3SMI died vs 64.6% of patients with normal L3SMI, HR =1.683, 95% CI 1.102--2.573, *p*=0.015). Comorbidities were not found to be associated with increased risk of mortality, including ischemic heart disease, diabetes mellitus, state post cerebrovascular disease, chronic kidney disease and chronic obstructive pulmonary disease. Lower ALT values were not found to be associated with increased risk of mortality, either as a categorical or as a continuous variable.Table 3Univariate analysis of patients' characteristics associated with mortality (% indicated are within-mortality group, defined at the end of the follow-up duration)Patient characteristicsAlive (n=38)Dead (n=102)HR (95% Cl)*p*-valueMale21 (55.3%)58 (56.9%)1.000.364Female17 (44.7%)44 (43.1%)0.833 (0.562--1.2360)Age (years), median (IQR)66 (62--73)66 (61--74)1.009 (0.987--1.033)0.412Weight (kg), median (IQR)71 (62.75--80)69.85 (60--78.925)1.00 (0.987--1.014)0.971Married32 (84.2%)73 (71.65%)1.000.059Single1 (2.6%)4 (3.9%)1.142 (0.417--3.130)Widowed4 (10.5%)12 (11.8%)1.204 (0.652--2.222)Divorced1 (2.6%)13 (12.7%)2.285 (1.259--4.146)**Performance status**022 (57.9%)32 (31.4%)1.00**\<0.001**113 (34.2%)36 (35.3%)1.727 (1.062--2.809)\>23 (7.9%)34 (33.3%)3.9 (2.362--6.441)**Disease stage**110 (26.3%)6 (5.9%)1.00**0.001**26 (15.8%)10 (9.8%)1.955 (0.71--5.38)310 (26.3%)35 (34.3%)3.473 (1.455--8.291)412 (31.6%)51 (50.4%)4.654 (1.991--10.879)Low L3SMI, n (%)21 (55.3%)71 (69.6%)1.683 (1.102--2.573)**0.015**Ischemic heart disease9 (23.7%)26 (25.5%)1.092 (0.699--1.706)0.7Chronic kidney disease1 (2.6%)6 (5.9%)0.917 (0.401--2.095)0.837Diabetes mellitus8 (21.1%)19 (18.6%)0.953 (0.578--1.57)0.849Cerebrovascular disease2 (5.3%)6 (5.9%)1.361 (0.595 −3.115)0.466COPD3 (7.9%)15 (14.7%)1.154 (0.667 −1.997)0.608ALT (IU/L), median (IQR)17 (10.75--25.50)17.5 (13--23.25)0.994 (0.971--1.016)0.58ALT \<17 IU/L (N, %)17 (44.7%)48 (47.1%)1.217 (0.824--1.796)0.324Creatinine (mg/dL), median (IQR)1 (0.895--1.0825)0.87 (0.7975--1.0825)0.804 (0.332--1.949)0.629Albumin (IU/L), mean±SD3.9±0.453.7±0.520.505 (0.343--0.742)**\<0.001**Hemoglobin (IU/L), mean±SD12.65±1.5912.48±1.810.933 (0.832--1.045)0.231[^5]

While several patients' characteristics were not found to be associated with increased risk of mortality (sex, age, weight and comorbidities), others were significantly associated with increased mortality: in comparison to patients with a good ECOG performance status (0), patients with higher ECOG scores had higher risk for death (for ECOG =1, HR =1.727; 95% CI 1.062--2.809; for ECOG ≥2, HR =3.9; 95% CI 2.362--6.441). Relative to patients with a lower disease stage upon diagnosis (1), patients at higher stages were at increased risk for mortality (for stage 2, HR =1.955; 95% CI 0.71--5.38, *p*=0.195; for stage 3, HR =3.473; 95% CI 1.455--8.291, *p*\<0.001; for stage 4, HR =4.654; 95% CI 1.99--10.879, *p*\<0.001). Higher concentration of blood albumin was found to be associated with decreased risk of mortality (3.7±0.52 vs 3.9±0.45, HR =0.505; 95% CI 0.343--0.742, *p*\<0.001).

Multiple regression analysis of parameters associated with increased risk of mortality {#S0005-S2005}
--------------------------------------------------------------------------------------

Results of the multiple regression analysis are presented in [Table 4](#T0004){ref-type="table"}. Worse ECOG PS (score ≥2 vs 0, HR =4.293, 95% CI 2.282--8.073, *p*\<0.001), advanced disease stage upon diagnosis (stage 3 vs 1, HR =3.439, 95% CI 1.325--8.924, *p*=0.011; stage 4 vs 1 HR =6.076, 95% CI 2.345--15.741, *p*\<0.001) and low albumin blood concentration (HR =1.548, 95% CI 1.007--2.375, *p*=0.046) were all found to be significantly correlated with increased risk of mortality in this multivariate model. Low L3SMI was not found to be associated with mortality after being incorporated into a multiple regression analysis (*p*=0.334). After adjustment, patients with ECOG performance status score of "1" did not have a significantly higher risk for mortality compared to patients with ECOG PS score of "0".Table 4Multiple regression analysis of patient characteristics associated with mortalityPatient characteristicsHR (95% CI)*p*-valueAge (years)0.99 (0.967--1.013)0.389Sex -- female0.818 (0.544--1.230)0.335Low L3SMI1.249 (0.795--1.962)0.334Married1.000.401Single2.398 (0.733--7.851)Widowed1.393 (0.728--2.667)Divorced1.169 (0.605--2.261)**Performance status**01.00**\<0.001**11.42 (0.838--2.405)\>24.293 (2.282--8.073)**Disease stage**11.00**\<0.001**21.419 (0.47--4.291)33.439 (1.325--8.924)46.076 (2.345--15.741)Albumin (g/dL)0.646 (0.421--0.993)**0.046**Hemoglobin (g/dL)N/AN/AALT \<17 IU/LN/AN/A[^6]

Propensity score matching {#S0006}
=========================

Using propensity score matching, 34 pairs were matched. Within the matched cohort of 68 patients, patients with low L3SMI were found to be at higher risk compared to patients with normal L3SMI (HR =2.222, 95% CI 1.012--4.88, *p*=0.047). See [Figure 3](#F0003){ref-type="fig"}.Figure 3Kaplan--Meier mortality curve according to L3SMI after PSM.**Abbreviations:** L3SMI, L3 skeletal muscle index; PSM, propensity score matching.

Discussion {#S0007}
==========

In contrast to the cancer-related cachexia that shatters lung cancer patients, premorbid sarcopenia and frailty are patients' characteristics that set the stage for the future battle of patients with cancer. As such, baseline sarcopenia and frailty assessment could have a major role in determination of prognosis of NSCLC patients. Our study is not the first to investigate quantitative measures for sarcopenia evaluation in lung cancer patients. Focusing on imaging studies and related modalities, Kim et al[@CIT0014],[@CIT0015] have shown that sarcopenia, as determined by CT, could be used to predict prognosis in patients with small cell lung cancer (SCLC). Sjoblom et al[@CIT0022] have failed to demonstrate this correlation in NSCLC patients, but stated that further research is warranted to establish whether muscle measures should be integrated into routine practice to improve prognostic accuracy. In our study, lower L3SMI was found to be associated with increased risk of mortality when appreciated in a univariate analysis. We used L3SMI threshold values calculated by Martin et al on a Canadian population,[@CIT0021] as this population was assumed to be similar to the Israeli population in lifestyle and western culture. Asian researches, such as Kim and Zheng, noticed that western thresholds do not necessarily fit with their study populations, and adjusted accordingly.[@CIT0014],[@CIT0016] Indeed, different normal ranges and thresholds of L3SMI exist in the literature, each calculated to fit mortality trends of a specific population group.[@CIT0013],[@CIT0014],[@CIT0016],[@CIT0021] Therefore, more research is needed on larger cohorts in order to calculate an agreed-upon and prognostic relevant value.

Taking several patients' characteristics into a multiple regression analysis, the association of sarcopenia with mortality did not reach statistical significance. This finding could be viewed in several ways. One should take into account the short, overall survival of these patients' cohort. It may be reasonable to assume that sarcopenia develops at a slower rate when compared to this devastating disease similar to the results of other studies on rapid progressing cancers, such as pancreatic cancer.[@CIT0023],[@CIT0024] Therefore, sarcopenia would become more valuable, as a prognostic tool, in cases of prolonged survival, as in cases of other, less lethal cancer types which are evidently heterogeneous with regard to the impact of sarcopenia and frailty on survival[@CIT0013]

In this study population, low ALT levels were not found to be associated with shortened survival, in contrast to other studies which showed an association between low ALT levels and mortality in the general population.[@CIT0018],[@CIT0025],[@CIT0026] Nevertheless, a trend of association was demonstrated in males (correlation between ALT and L3SMI, using Spearman's Rho -- correlation coefficient of 0.241 \[*p*=0.058\]). Once again, this finding potentially indicates that the short survival of NSCLC patients would not "allow" them to go through a phase of prolonged, deteriorating cachexia and frailty before dying. The high rate of mortality (72.8%) in a relatively short follow-up duration in our cohort supports this hypothesis.

Both the stage of the disease at diagnosis and ECOG PS were found to be strong indicators of mortality in cancer patients, and are accepted as survival predictors worldwide. Accordingly, in our study patients with higher ECOG, PS had an increased HR for death. Importantly, low L3SMI values, indicating sarcopenia, were found to be correlated with poorer ECOG scores in males ([Figure 1](#F0001){ref-type="fig"}), while in female patients this correlation did not reach statistical significance.

Conclusion {#S0008}
==========

As advanced treatment modalities emerge in the field of disease-centered medicine and oncology, there is an increasing need for more patient-oriented personalized medicine. Frailty and sarcopenia evaluation are leading patient characteristics for such personalized approach. In this study, we have demonstrated that sarcopenia evaluation, by means of CT scan analysis and L3SMI calculation, has the potential to improve evaluation of NSCLC patients. We assume that prolonged survival may intensify the value of sarcopenia evaluation in the future.

Study limitations {#S0008-S2001}
-----------------

This is a retrospective study and therefore, causality could not be inferred from our data. The relatively small cohort size and the high mortality rates deny the ability to reach statistically significant conclusions regarding some of the study parameters being evaluated. Larger, prospective studies should be done in order to further evaluate the practical benefits of sarcopenia evaluation for lung cancer patients and define agreed-upon L3SMI sarcopenia threshold for the general population. In addition, prospective studies could better evaluate the yield of consecutive sarcopenia and frailty assessments along disease progression and treatment delivery. It should be stated that qualitative parameter of frailty was not available. Therefore, our findings are especially relevant for the muscle mass component of sarcopenia and frailty and do not address the whole phenotype of these syndromes.
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